|Elimination half-life||12–14 hours|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||452.587 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Diphenoxylate is a centrally active opioid drug of the phenylpiperidine series that is used in a combination drug with atropine for the treatment of diarrhea. Diphenoxylate is an opioid and acts by slowing intestinal contractions; the atropine is present to prevent drug abuse and overdose. It should not be given to children due to the risk that they will stop breathing and should not be used in people with Clostridium difficile infection.
It should not be used for people with diarrhea caused by an infection, for example with Clostridium difficile infection, since the slowing of peristalsis can prevent clearing of the infectious organism.
The drug label has warnings with regard to the risk of respiratory depression, anticholinergic toxicity and opioid overdose, the risk of dehydration and electrolyte imbalance that people with severe diarrhea always run, and toxic megacolon in people with ulcerative colitis.
Other adverse effects include numbness in the hands and feet, euphoria, depression, lethargy, confusion, drowsiness, dizziness, restlessness, headache, hallucinations, edema, hives, swollen gums, itchiness, vomiting, nausea, loss of appetite, and stomach pain.
Like other opioids, diphenoxylate acts by slowing intestinal contractions, allowing the body to consolidate intestinal contents and prolong transit time, thus allowing the intestines to draw moisture out of them at a normal or higher rate and therefore stop the formation of loose and liquid stools; the atropine is an anticholinergic and is present to prevent drug abuse and overdose.
History and chemistry
Diphenoxylate is made by combining a precursor of normethadone with norpethidine. Loperamide (Imodium) and bezitramide are analogs.  Like loperamide, it has a methadone-like structure and a piperdine moiety.
Society and culture
It is on Schedule III of the Single Convention on Narcotic Drugs, only in forms that contain, according to the Yellow List: "not more than 2.5 milligrams of diphenoxylate calculated as base and a quantity of atropine sulfate equivalent to at least 1 per cent of the dose of diphenoxylate".
Diphenoxylate and atropine have been studied in small trials as a treatment for fecal incontinence; it appears to be less efficacious and have more adverse effects when compared with loperamide or codeine.
- "US label: Diphenoxylate hydrochloride and atropine sulfate tablets" (PDF). FDA. 12 February 2018. For label updates see FDA index page for NDA 012462
- Stern, J; Ippoliti, C (November 2003). "Management of acute cancer treatment-induced diarrhea". Seminars in Oncology Nursing. 19 (4 Suppl 3): 11–6. doi:10.1053/j.soncn.2003.09.009. PMID 14702928.
- Florey, Klaus (1991). Profiles of Drug Substances, Excipients and Related Methodology, Volume 19. Academic Press. p. 342. ISBN 9780080861142.
- Casy, A. F.; Parfitt, R. T. (2013). Opioid Analgesics: Chemistry and Receptors. Springer Science & Business Media. p. 312. ISBN 9781489905857.
- Patrick, Graham L. (2013). An Introduction to Medicinal Chemistry. OUP Oxford. p. 644. ISBN 9780199697397.
- Crow, David (20 August 2017). "Hikma hikes price of US medicines by up to 430%". Financial Times.
- "Diphenoxylate". MedlinePlus. 15 April 2018. Retrieved 10 May 2018.
- "Yellow List: List of Narcotic Drugs Under International Control, 50th Edition" (PDF). International Narcotics Control Board. 2011. p. 8. Retrieved 10 May 2018.
- Omar, MI; Alexander, CE (11 June 2013). "Drug treatment for faecal incontinence in adults". The Cochrane Database of Systematic Reviews (6): CD002116. doi:10.1002/14651858.CD002116.pub2. PMID 23757096.